Aravive, Inc. (ARAV) SEC Filing 8-K Material Event for the period ending Thursday, March 31, 2022

Aravive, Inc.

CIK: 1513818 Ticker: ARAV

View differences made from one to another to evaluate Aravive, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aravive, Inc..


Assess how Aravive, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aravive, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Aravive, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ARAV
CIK: 1513818
Form Type: 8-K Corporate News
Accession Number: 0001437749-22-007951
Submitted to the SEC: Fri Apr 01 2022 7:05:34 AM EST
Accepted by the SEC: Fri Apr 01 2022
Period: Thursday, March 31, 2022
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: